Pfizer Inc. (NYSE:PFE) Receives Consensus Recommendation of "Hold" from Brokerages

Shares of Pfizer Inc. (NYSE:PFE - Get Free Report) have earned an average rating of "Hold" from the twenty-two research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, five have issued a buy rating and three have given a strong buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $28.55.

Several research firms recently commented on PFE. TD Cowen cut their price target on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a report on Tuesday, April 22nd. The Goldman Sachs Group upped their price target on shares of Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Cantor Fitzgerald began coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective on the stock. Citigroup upped their target price on Pfizer from $23.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Finally, BMO Capital Markets dropped their target price on Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th.

Hedge Funds Weigh In On Pfizer

Large investors have recently modified their holdings of the company. QRG Capital Management Inc. increased its stake in Pfizer by 8.6% in the 2nd quarter. QRG Capital Management Inc. now owns 759,903 shares of the biopharmaceutical company's stock worth $18,420,000 after purchasing an additional 59,948 shares during the period. Corundum Group Inc. increased its stake in shares of Pfizer by 3.0% during the second quarter. Corundum Group Inc. now owns 32,175 shares of the biopharmaceutical company's stock valued at $780,000 after buying an additional 934 shares during the period. Franklin Street Advisors Inc. NC increased its stake in shares of Pfizer by 27.0% during the second quarter. Franklin Street Advisors Inc. NC now owns 54,831 shares of the biopharmaceutical company's stock valued at $1,329,000 after buying an additional 11,668 shares during the period. Stock Yards Bank & Trust Co. increased its stake in shares of Pfizer by 0.6% during the second quarter. Stock Yards Bank & Trust Co. now owns 93,054 shares of the biopharmaceutical company's stock valued at $2,256,000 after buying an additional 551 shares during the period. Finally, HighMark Wealth Management LLC increased its stake in shares of Pfizer by 123.7% during the second quarter. HighMark Wealth Management LLC now owns 4,249 shares of the biopharmaceutical company's stock valued at $103,000 after buying an additional 2,350 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of Pfizer stock opened at $24.27 on Tuesday. The stock has a 50 day moving average of $24.07 and a 200 day moving average of $24.71. Pfizer has a 12 month low of $20.92 and a 12 month high of $31.54. The firm has a market cap of $137.96 billion, a PE ratio of 17.58, a PEG ratio of 0.89 and a beta of 0.58. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.82 earnings per share. On average, research analysts expect that Pfizer will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.09%. Pfizer's dividend payout ratio is currently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.